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Development of a Corynebacterium glutamicum bio-factory for 
self-sufficient transaminase reactions.
Stylianos Grigoriou,a Pierre Kugler,b Evelina Kulcinskaja,a Frederik Walter,a John King,a Phil Hill,a 
Volker F. Wendisch,b and Elaine O’Reilly*a,c
The development of biocatalytic routes for the synthesis of chiral 
amines starting from achiral building blocks is highly desirable. 
Here, we report a self-sufficient whole-cell system for the 
conversion of a model ketone to the corresponding cyclic imine, in 
good isolated yield (42%) and excellent enantioselectivity (>99% 
ee). The Corynebacterium glutamicum host produces the 
transaminase biocatalyst, cofactor and ‘smart’ amine donor 
(cadaverine or putrescine) in vivo, and highlights the potential for 
producing high-value chemicals from readily available building 
blocks. The report represents the first example of the application of 
a metabolically engineered organism for the production of smart 
diamine donors and their application in a transaminase 
biotransformation.
Rapid progress in synthetic biology has enabled the 
development of efficient biocatalytic systems for the 
production of fine chemicals and amino acids.1–7 The 
exceptional levels of regio- and stereoselectivity associated 
with enzymes means that extremely efficient routes to target 
molecules can be devised that avoid the need for protecting 
group manipulations and costly intermediate purification steps 
and enable the design of multi-enzyme cascades.8–11 The 
aqueous media and mild conditions employed can provide a 
cost-effective and sustainable synthetic route to target 
molecules. As protein purification can be expensive and time-
consuming, the application of whole-cell systems represents an 
attractive alternative to isolated enzymes and significantly 
reduces upstream costs.12,13 The stable intracellular 
environment of the host cells, as well as the ability to 
regenerate essential cofactors and/or co-express multiple 
enzymes in a single organism, constitute attractive features for 
synthetic applications. 
Amine transaminases (ATAs) represent an extremely important 
enzyme family for the synthesis of chiral amines. These proteins 
rely on pyridoxal 5’-phosphate and a sacrificial amine donor to 
convert a range of aldehydes, ketones and ketoacids to the 
corresponding (chiral) amines or amino acids.14–20 In recent 
years, considerable effort by our own group and others has 
focused on the development of methodology that effectively 
displaces the challenging reaction equilibrium towards product 
formation.21–25 The use of ‘smart’ amine donors, where 
coproducts tautomerize,21 dimerize,25 cyclize22,23 and 
polymerize,24 have been shown to enable high conversions to 
the desired amine product. Our group recently reported that 
cadaverine functioned as an excellent amine donor in 
transaminase-mediated biotransformations and allowed the 
conversion of a series of ketones to the corresponding chiral 
amines (Scheme 1 (a)).22, 26 Putrescine has also been shown to 
act as an amine donor for some ATAs.23
Scheme 1. a) Use of ‘smart’ diamine donors for effective 
equilibrium displacement of transaminase-mediated 
biotransformations.22,23,26 b) Proposed whole-cell 
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biotransformation, using engineered C. glutamicum cells that 
produce diamine donors.
Corynebacterium glutamicum has been used for the industrial 
production of L-amino acids for decades and more recently 
been applied for the preparation of a wide variety of small 
molecules and polymers.7, 27-29 C. glutamicum ATCC13032 was 
engineered to produce putrescine (1,4-diaminobutane)30,31 
(strain named NA6) and cadaverine32 (1,5-diaminopentane) 
(strain named Cada1), starting from glucose and ammonium 
salts. We envisaged that these strains could be employed for 
the design of a whole-cell biocatalyst, capable of the in-situ 
production of the ATA, PLP coenzyme and ‘smart’ amine donor 
(Scheme 1(b)). Kim et al. previously reported a recombinant C. 
glutamicum strain that was engineered to overproduce non-
natural amino acids via a transaminase reaction.33 While the 
work highlighted the potential of self-sufficient systems, the α-
transaminase employed is limited to α-amino and α-keto acid 
substrates and the report does not include the isolation of final 
products. The flexible system proposed herein allows the 
preparative-scale synthesis of high-value chiral products, 
starting from inexpensive sources, and represents the first 
example of the production and application of a self-sufficient 
whole-cell system, overproducing smart amine donors.
In order to identify suitable ATA candidates for the C. 
glutamicum system, a small panel of (R)- and (S)-selective ATAs 
were screened against the ‘smart’ amine donors cadaverine, 
putrescine and o-xylylenediamine (table S1). O-xylylenediamine 
was included for comparison and also to establish if the 
compound could be used for in a colorimetric assay to identify 
efficient C. glutamicum whole-cell systems. Three ketones (1-3) 
were selected to explore the efficiency of these donors, based 
on the difficulty associated with displacing the reaction 
equilibrium towards product formation.[24] Negligible activity 
was observed for the (R)-selective ATAs with all substrates. Four 
(S)-selective ATAs were identified from Silicibacter pomeroyi 
(referred by its PDB code: 3HMU),34 Pseudomonas species 
namely; P. chlororaphis ssp. aerofaciens (PcATA), P. flurescens 
(PfATA) and P. putida (PpATA),23 which were capable of 
mediating the transamination of ketones 1-3 in poor to high 
conversion (up to 75%), using only 1 equivalent of amine donor 
4-6 (table 1).  Significantly, 3HMU achieved conversions of >70% 
with diketone 1, regardless of the amine donor employed. The 
other ω-TAs screened were considerably more efficient at 
converting 1 to the corresponding amine using cadaverine (40-
55%), compared to those conversions achieved when 
putrescine or o-xylylenediamine was employed as the amine 
donor. Ketone 2 was relatively poorly converted in all cases, 
with a maximum of 25% conversion achieved when PfATA was 
used in combination with cadaverine. Previous reports 
employing higher enzymatic loadings with these ATAs have 
shown comparable conversions of 2 to the corresponding chiral 
amine in the presence of ‘smart’ amine donors.23,25 To 
effectively demonstrate the methodology, the transamination 
of ketone 1 with 3 equivalents of cadaverine utilizing 3HMU, 
PcATA, PfATA or PpATA was explored (Table 1, entry 10). A 
significant improvement was observed, reaching up to 99% 
conversion with 3HMU and 80% with PcATA.
Next, the in vivo production of ‘smart’ amine donors 4 and 5 by 
C. glutamicum was examined, by monitoring the conversion of 
model ketone 1 to the corresponding cyclic imine, using the 
bacterial culture medium as the sole source of amine donor. For 
these early studies, strains expressing the ATA genes were not 
employed, but rather the enzyme was supplied externally. The 
biotransformations with C. glutamicum strains (GRLys1, NA6 
and Cada1) were carried out in conditioned medium (cell-free 
lysate) of one- or two-day mature culture, supplemented with 
purified ATA (1 mg mL-1) and ketone 1 (5 mM) (see Table S2). In 
all cases, conversions were significantly higher (60-98%) than 
those achieved when 1 equivalent of donor 4 was exogenously 
supplied (Table 1) and were comparable to those achieved using 
3 equivalents of the same donor (Table 1, Entry 10). 
Interestingly, up to 15% conversion was observed for 
biotransformations involving the conditioned media from C. 
glutamicum GRLys1. GRLys1, which is used in this study, has 
been engineered to overproduce L-lysine,2 and conversions of 1 
to the corresponding imine in the presence of GRLys1 media
Table 1. Initial screen to establish the amine donor (4-6) 
substrate scope of a small panel of TAs, by evaluating their 
ability to convert ketones 1-3 to the corresponding chiral amine. 
Clarified crude extract (1.5 mg mL-1) and 1 equiv. ‘smart’ amine 
donor. Ee values for all were >99%, with the exception of ketone 
acceptor 2, where ee values were between 80-85% (see Table 
S1 for full details).
Conversions of 5 mM of 1, 2 or 3 to the corresponding chiral 
amine utilizing 1.5 mg mL-1 clarified crude extract 3HMU, Pc, Pf 
or Pp ATA, 0.1 mM PLP and 5 or 15 (entry 10) mM cadaverine at 
30°C, 200 rpm, 24h.
      Conversion (%) 






1 1 4 1 75 43 54 53
2 1 5 1 72 20 28 24
3 1 6 1 74 23 35 25
4 2 4 1 21 14 25 18
5 2 5 1 19 6 9 9
6 2 6 1 20 8 17 11
7 3 4 1 nd nd 9 nd
8 3 5 1 nd nd nd nd
9 3 6 1 nd nd 7 nd
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likely arise due to L-lysine acting as an amine donor. This amino 
acid donor itself has the potential to function as a ‘smart’ amine 
donor, since the coproduct has the ability to cyclise and displace 
the reaction equilibrium towards product formation.35 All four 
ATAs were tested on ketone 1, utilizing 1 or 3 equivalents of L-
lysine as the amine donor (Table S3). However, only 3HMU 
showed measurable conversion (up to 16%), supporting our 
observations in the presence of C. glutamicum GRLys1. 
Subsequently, the four ATA candidates were cloned into the 
engineered strains with the aim of generating a self-sufficient 
whole-cell system. A solid-phase screen, employing o-
xylylenediamine,24 was used to detect transaminase activity 
from the newly transformed strains (Figure 1). Dark colonies 
were observed for Pc, Pf and PpATA, indicating transaminase 
activity. However, no colour change was observed for strains 
transformed with the 3HMU gene. To explore possible reasons 
for the lack of ATA activity with 3HMU, further investigations on 
transformants harboring this gene were carried out. Initially, 
the 3HMU sequence was investigated for the presence of rare 
codons, but this was quickly ruled out. We hypothesized that 
potential toxicity associated with 3HMU activity could hamper 
the expression or lead to inactive mutants. To that end, the 
catalytic lysine residue (K292) was mutated to alanine, using 
site-directed mutagenesis. The resulting 3HMU variant was 
expressed in E. coli BL21-(DE3) and its activity assessed using 
the acetophenone assay37 (data not shown). As expected, the 
mutant displayed no detectable activity. Gene expression in C. 
glutamicum strains was examined using SDS-PAGE and MALDI-
TOF analysis, and the results showed that no detectable 
quantity of the inactive mutant was expressed (data not 
shown). At this point, we rationalized that complications at a 
transcription level may hamper 3HMU expression, but this was 
not investigated further in this study and instead, our efforts 
concentrated on the active putrescine ATAs that gave colored 
colonies.
Figure 1. Sample plate showing the emergence of dark colonies 
when o-xylylenediamine is used in combination with 
recombinant C. glutamicum strains.
Positive transformants of both putrescine (NA6) and cadaverine 
(Cada1)-producing C. glutamicum strains, overexpressing the 
Pc, Pf or Pp ATA genes, were carried forward and tested under 
biotransformation conditions at both 30 C and 37 C (Table S4). 
However, both strains performed poorly, with a maximum 
conversion of 12% observed for C. glutamicum NA6 
overexpressing the PcATA (Table S4). We speculated there were 
two reasons for the observed poor performance of these ATAs. 
Firstly, the ATAs studied retain less than 20% activity in the 
intracellular neutral pH. This was verified by measuring the 
specific activity at different pH values of purified extracts of Pc, 
Pf and Pp ATAs utilizing the acetophenone assay (Figure S3). 
Secondly, a low copy number plasmid, pEKEx3,38,39 was used to 
host the ATAs, due to its compatibility with the pre-existing 
plasmid pVWEx1,40 which harbors the genes encoding the lysine 
decarboxylase (ldcC) or ornithine decarboxylase (speC) that are 
essential for the production of cadaverine[32] and 
putrescine,30,31 respectively. Following previous reports in the 
literature,8 we envisaged enhancing gene expression by 
introducing a second copy of the PcATA gene into the pEKEx3 
vector. A slight increase was observed, reaching up to 32% after 
48 h in the presence of the C. glutamicum NA6 strain, which 
produces putrescine (Table S5). In order to further optimize the 
whole-cell system, we sought to co-express the ATAs with the 
ldcC or speC in the high-copy number vector pVWEx1. Due to 
the size of the new plasmids, the production of putrescine was 
compromised and the less efficient NA2b strain was used 
instead. The NA2b strain has also been engineered to produce 
putrescine, but it does so less efficiently than the NA6 strain of 
C. glutamicum.
The NA2b and GRLys1 strains, harboring the high copy number 
plasmid and IdcC or speC genes were tested under the same 
reaction conditions. A significant drop to 8% was observed for 
all the NA2b transformants, whereas conversions significantly 
increased for the GRLys1 strains, reaching up to 41% (Table S6).
C. glutamicum GRLys1 co-expressing ldcC and PcATA in the 
pVWEx1 vector was identified as the best whole-cell system, 
and further optimization was carried out. We envisaged that 
using a higher concentration of cells would correspond to more 
biocatalyst and result in increased conversions. The conversion 
of diketone 1 to pyrroline 7 was evaluated, using various 
concentrations of cells resuspended in HEPES buffer or in the 
original culture media. The aim of this study was to establish if 
the amine donor was being utilized from within the cell or after 
it has been released into the culture media. Conversions 
reached a plateau at 73-77%, when 100 mg mL-1 or more of wet 
cells were employed (Figure 2). The addition of external PLP was 
also tested, but this had no impact on the conversions, 
indicating that C. glutamicum cells are producing sufficient 
coenzyme to support the expressed ATAs. In parallel, 
biotransformations were carried out in recovered culture 
media, which afforded comparable conversions. These results 
demonstrate cells either remain metabolically active and 
continue producing cadaverine, or the intracellular levels of 
cadaverine are high enough for the biotransformation to occur.
The reusability of this system was tested, by utilizing the 
cells in three consecutive cycles (Table S7). The cells were 
washed after each cycle to ensure no product was carried 
forward and this was verified by GC-FID. The results indicate 
that the whole cells can be reused once, with minimal loss in 
activity, whereas a significant drop to 22% was observed during 
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Figure 2. Conversion of 1 in the presence of different cell 
densities of C. glutamicum GRLys1 whole-cells, overexpressing 
ldcC and PcATA.
the third cycle. This decrease in activity is unsurprising, and 
likely to be a result of diminishing enzyme activity as well as a 
reduction in the levels of amine donor available, in the absence 
of culture media.
 To demonstrate the industrial potential of our system, a 
preparative-scale biotransformation, utilizing 100 mg mL-1 wet 
cells in buffer, was performed on the model ketone substrate 1 
(5 mM) affording the enantiomerically pure (>99% ee) (S)-
pyrroline 7 with 42% isolated yield (Scheme 2).
 
Scheme 2. Preparative-scale biotransformation of 1 to imine 7, 
using 100 mg mL-1 of wet cells.
Conclusions
In summary, we have developed the first whole-cell system 
for the co-production of an ω-TA and sacrificial ‘smart’ amine 
donor. Optimization of reaction conditions for the best 
biocatalyst enabled the preparation of multi-milligram 
quantities of a chiral pyrroline product, starting from the 
corresponding commercially available pro-chiral diketone. Our 
system has the potential to provide a sustainable platform for 
the development of an array of whole-cell ω-TAs biocatalysts 
that rely on smart amine donors to displace the challenging 
reaction equilibrium towards product formation, negating the 
need for the external supply of co-substrate. Before this goal 
can be realized, the activity of a wide range of ATAs towards a 
more diverse ketone panel must be evaluated in these 
engineered C. glutamicum cells, as high conversion using this 
methodology is currently limited to one model substrate. 
However, we are extremely confident that excellent activity 
towards other ketones can be achieved with alternative ATAs, 
based on previous work reported in our group, which shows 
high conversions with just 1 equivalent of these smart amine 
donors. Significantly, this work demonstrates that better 
conversions are achieved using conditioned media containing 
the diamines, compared to those afforded when 1 equivalent of 
the amine donor is exogenously supplied (Table S2).  The 
putrescine ATAs (Pc, Pf and PpATA) used in this study require 
very high enzyme loadings for good activity towards ketones 
and this goes some way to explaining why substrates 2 and 3 
were not efficiently converted to the corresponding chiral 
amines when expressed in engineered C. glutamicum cells.  
With further development, this system could be used to 
develop in vivo biocatalytic cascades towards high-value chiral 
molecules, by the introduction of additional genes into the C. 
glutamicum cells. 
Our system already performs broadly well (non-hazardous 
solvents, use of catalysts, health and safety) when assessed 
using a recently developed Zero Pass Metrics Toolkit, which 
aims to evaluate the ‘greenness’ of a process.41 However, it is 
also important to note that these metrics are not easily applied 
to in vivo systems, where reagents, catalysts and cofactors are 
produced by the host cell and highlights the need for a set of 
guidelines to assess the sustainability of whole-cell systems.
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